Analyst
Needham
Equibles does not estimate personal net worth.
Serge Bellinger is recorded as Analyst at Needham. Serge Bellinger has spoken on 8 earnings calls and 1 other investor event across 6 companies, most recently for Omeros Corp on August 12, 2026. Those appearances were for Omeros Corp (OMER), Liquidia Corp (LQDA), Heron Therapeutics, Inc. (HRTX), Pacira BioSciences, Inc. (PCRX), Collegium Pharmaceutical, Inc (COLL) and 1 other company. The companies whose calls Serge Bellinger spoke on are classified in the Healthcare sector.
“First, on your Temlia, Greg, can you just talk about maybe the number of patients that have so far been treated with the product and, I guess, what the market share of the overall opportunity would be based on those patients?”
“It's my pleasure to welcome you to our second quarter 2026 Financial Result and Corporate Update Call.”
“I guess first one for Craig on potential generic Sinventi. I know there's still a lack of clarity on a potential launch here, but I believe you have a couple settlement agreements around Sinventi with some other players.”
“I guess just a follow-up on Expero, volume growth of 4%, a bit of a step down from the prior quarters. I'm just curious if the softness that you've seen in the second quarter has continued into the third quarter and could continue later in the summer.”
“I guess a few on just to get a little more granularity on the 1Q sales number. Greg, can you disclose what the number of vials that were, I guess, dispersed from your distributor over the quarter?”
Needham
Analyst
Transcript header (unverified)
OMER
Biotechnology · Healthcare
LQDA
Drug Manufacturers - Specialty & Generic · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
